Results 201 to 210 of about 323,586 (342)
Pre-transplant antibodies IgA-anti Beta 2 Glycoprotein I
Transplantation, 2018 Manuel Serrano Blanco +12 more
openaire +2 more sources
Cellular Identity Crisis: RD3 Loss Fuels Plasticity and Immune Silence in Progressive Neuroblastoma
Advanced Science, EarlyView.Researchers discovered that therapy‐induced loss of RD3 protein in neuroblastoma triggers a dangerous shift: cancer cells become more stem‐like, invasive, and resistant to treatment while evading immune detection. RD3 loss suppresses antigen presentation and boosts immune checkpoints, creating an immune‐silent environment.
Poorvi Subramanian +7 more
wiley +1 more source
Lupus anticoagulant activity of some antiphospholipid antibodies against phospholipid bound beta 2 glycoprotein I. [PDF]
, 1993 David Keeling +4 more
openalex +1 more source
Traceless Regulation of Genetic Circuitry
Advanced Science, EarlyView.Energy‐based, as opposed to molecular, control offers unprecedented improvements in key circuit parameters. This review summarizes the fundamentals of such traceless switches, categorizes them by trigger modalities, and compares and contrasts distinct advantages as well as shortcomings of each kind.
Gokberk Unal, Martin Fussenegger
wiley +1 more source
Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APS. [PDF]
BMC Biotechnol, 2015 McDonnell T +7 more
europepmc +1 more source
T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities
Advanced Science, EarlyView.T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu +7 more
wiley +1 more source
Engineered CAR‐NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity
Advanced Science, EarlyView.TM4SF1‐nanobody engineered CAR‐natural killer T–derived extracellular vesicles (CARTM4SF1‐EVs) provide a cell‐free alternative to CAR‐NKT therapy, achieving potent, targeted antitumor activity with reduced toxicity. CARTM4SF1‐EVs induce immunogenic cell death, remodel the tumor microenvironment, and enhance CD8⁺ T‐cell antitumor immunity.
Xiaopei Hao +14 more
wiley +1 more source